Pcsk9 inhibition and risk of diabetes: should we worry?

HIGHLIGHTS

• who: Stefano Carugo from the Department of Clinical Sciences and Community Health, Universitu00e0 Degli Studi Di Milano, Milan, Italy have published the article: PCSK9 Inhibition and Risk of Diabetes: Should We Worry?, in the Journal: (JOURNAL)
• what: A confirmation came also by the results of a further post hoc analysis aimed at assessing the efficacy and safety of evolocumab in patients with and without diabetes . The trial showed that there was neither an increment in the cumulative incidence of NOD in the evolocumab and placebo treatment groups at the end of 1, 2 and 3 . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.